financetom
Business
financetom
/
Business
/
Exclusive-Mars readying over $25 billion bond sale for next week, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive-Mars readying over $25 billion bond sale for next week, sources say
Feb 28, 2025 2:39 PM

NEW YORK (Reuters) - Family-owned candy giant Mars is preparing to sell bonds worth between $25 billion and $30 billion as soon as next week to help finance its takeover of Pringles maker Kellanova ( K ), according to people familiar with the matter, in a deal that would headline a $40 billion rush of acquisition financing bonds.

Banks led by Citigroup and JPMorgan Chase ( JPM ) are preparing to market the bond sale to potential investors sometime next week, the sources said, cautioning that the timing of the bonds sale is subject to market conditions and could change.

Depending on its final size, the bonds offering could feature among the top 10 largest M&A financing deals in the investment-grade bond market since 2013, according to Informa Global Markets data.

Separately, design software maker Synopsys ( SNPS ) is preparing to sell between $10-15 billion of bonds to help finance its $34 billion takeover of Ansys ( ANSS ), two of the sources added. Bloomberg earlier on Friday reported on Synopsys' ( SNPS ) bond sale talks.

The two deals combined could result in issuances worth about $40 billion next week, the sources said, boosting supply in an investment-grade bond market that is already seeing a flood of issuance driven by investor demand to lock in yields in a high-for-longer interest rate environment.

JPMorgan ( JPM ) and Citigroup declined to comment. Mars and Synopsys ( SNPS ) did not immediately respond to requests for comment.

On Thursday, S&P Global Ratings downgraded its issuer credit rating on Mars to A from A+ noting the company expects to fund its Kellanova ( K ) acquisition entirely with net debt.

"We do not forecast the company will restore leverage to below 3x or sustain discretionary cash flow (DCF) to debt well above 10% until fiscal 2027. We expected the company to maintain those metrics for the 'A+' rating," S&P said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved